IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update
IGM Biosciences, Inc. (IGMS)
Last igm biosciences, inc. earnings: 3/26 04:05 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
– Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 – – IGM-2644 (CD38 x CD3) expected to enter clinical study for generalized myasthenia gravis by year-end 2024 – – Cash runway expected to fund operations into 2027 – MOUNTAIN VIEW, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended September 30, 2024 and provided an update on recent developments. “The third quarter was transformative for IGM, punctuated by the announcement of our strategic pivot to focus exclusively on autoimmunity,” said Mary Beth Harler, M.D., Chief Executive Officer of IGM Biosciences. "Our near-term focus for imvotamab remains generating robust initial data sets in rheumatoid arthritis, systemic lupus erythematosus and
Show less
Read more
Impact Snapshot
Event Time:
IGMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IGMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IGMS alerts
High impacting IGM Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
IGMS
News
- IGM Biosciences, Inc. (NASDAQ: IGMS) had its price target raised by analysts at Stifel Nicolaus from $25.00 to $27.00. They now have a "buy" rating on the stock.MarketBeat
- IGM Biosciences GAAP EPS of -$1.01 misses by $0.19, revenue of $0.52M beats by $0.28M [Seeking Alpha]Seeking Alpha
- IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]Yahoo! Finance
- Medivir AB (OSTO:MVIR) Q3 2024 Earnings Call Highlights: Strategic Collaborations and Financial ... [Yahoo! Finance]Yahoo! Finance
- IGM Biosciences to Present at Three Upcoming Investor ConferencesGlobeNewswire
IGMS
Earnings
- 11/8/24 - Miss
IGMS
Sec Filings
- 11/20/24 - Form 4
- 11/14/24 - Form SC
- 11/12/24 - Form 4
- IGMS's page on the SEC website